cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.
Company profile
Ticker
CERS
Exchange
Website
CEO
William Greenman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Cerus Europe ...
IRS number
680262011
CERS stock data
Latest filings (excl ownership)
8-K
Other Events
19 Mar 24
10-K
2023 FY
Annual report
5 Mar 24
8-K
Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results
5 Mar 24
8-K
Year 2023 Product Revenue and Provides Business Update
8 Jan 24
8-K
Entry into a Material Definitive Agreement
5 Jan 24
EFFECT
Notice of effectiveness
16 Nov 23
CORRESP
Correspondence with SEC
13 Nov 23
UPLOAD
Letter from SEC
9 Nov 23
S-8
Registration of securities for employees
2 Nov 23
S-3
Shelf registration
2 Nov 23
Transcripts
CERS
Earnings call transcript
2023 Q4
5 Mar 24
CERS
Earnings call transcript
2023 Q3
2 Nov 23
CERS
Earnings call transcript
2023 Q2
2 Aug 23
CERS
Earnings call transcript
2023 Q1
4 May 23
CERS
Earnings call transcript
2022 Q4
28 Feb 23
CERS
Earnings call transcript
2022 Q3
3 Nov 22
CERS
Earnings call transcript
2022 Q2
4 Aug 22
CERS
Earnings call transcript
2022 Q1
6 May 22
CERS
Earnings call transcript
2021 Q4
23 Feb 22
CERS
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
4
Kevin Dennis Green
14 Mar 24
4
Carol Moore
14 Mar 24
4
Chrystal Jensen
14 Mar 24
4
Vivek K Jayaraman
14 Mar 24
4
William Mariner Greenman
14 Mar 24
4
LAURENCE M CORASH
14 Mar 24
4
Richard J Benjamin
14 Mar 24
4
Richard J Benjamin
12 Mar 24
144
Notice of proposed sale of securities
8 Mar 24
4
Carol Moore
5 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 19.16 mm | 19.16 mm | 19.16 mm | 19.16 mm | 19.16 mm | 19.16 mm |
Cash burn (monthly) | 1.09 mm | 976.17 k | 2.40 mm | 4.11 mm | 3.50 mm | 2.48 mm |
Cash used (since last report) | 7.44 mm | 6.67 mm | 16.41 mm | 28.10 mm | 23.88 mm | 16.93 mm |
Cash remaining | 11.72 mm | 12.49 mm | 2.75 mm | -8.94 mm | -4.72 mm | 2.23 mm |
Runway (months of cash) | 10.8 | 12.8 | 1.1 | -2.2 | -1.4 | 0.9 |
Institutional ownership, Q3 2023
80.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 140 |
Opened positions | 18 |
Closed positions | 33 |
Increased positions | 42 |
Reduced positions | 45 |
13F shares | Current |
---|---|
Total value | 232.91 bn |
Total shares | 145.79 mm |
Total puts | 44.50 k |
Total calls | 47.50 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
ARK Investment Management | 20.06 mm | $32.50 bn |
Baker Bros. Advisors | 17.24 mm | $27.93 bn |
BLK Blackrock | 13.93 mm | $22.56 bn |
Vanguard | 9.75 mm | $15.79 bn |
Primecap Management | 8.61 mm | $13.95 bn |
CMTDF Sumitomo Mitsui Trust | 7.91 mm | $12.82 bn |
Nikko Asset Management Americas | 7.91 mm | $12.74 bn |
Senvest Management | 7.26 mm | $11.76 bn |
Wasatch Advisors | 5.87 mm | $9.51 bn |
STT State Street | 4.96 mm | $8.04 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Mar 24 | Benjamin Richard J | Common Stock | Sell | Dispose S | No | Yes | 1.9744 | 17,738 | 35.02 k | 459,612 |
14 Mar 24 | Corash Laurence M | Common Stock | Sell | Dispose S | No | Yes | 1.9744 | 14,360 | 28.35 k | 2,339,740 |
14 Mar 24 | Greenman William Mariner | Common Stock | Sell | Dispose S | No | Yes | 2.0153 | 63,611 | 128.20 k | 3,181,281 |
14 Mar 24 | Jayaraman Vivek K | Common Stock | Sell | Dispose S | No | Yes | 1.9744 | 26,794 | 52.90 k | 878,653 |
13 Mar 24 | Benjamin Richard J | Common Stock | Sell | Dispose S | No | Yes | 2.057 | 17,377 | 35.74 k | 477,350 |
13 Mar 24 | Corash Laurence M | Common Stock | Sell | Dispose S | No | Yes | 2.057 | 14,067 | 28.94 k | 2,354,100 |
13 Mar 24 | Greenman William Mariner | Common Stock | Sell | Dispose S | No | Yes | 2.057 | 62,315 | 128.18 k | 3,244,892 |
13 Mar 24 | Jayaraman Vivek K | Common Stock | Sell | Dispose S | No | Yes | 2.057 | 26,247 | 53.99 k | 905,447 |
13 Mar 24 | Moore Carol | Common Stock | Sell | Dispose S | No | Yes | 1.9744 | 10,416 | 20.57 k | 490,623 |
13 Mar 24 | Moore Carol | Common Stock | Sell | Dispose S | No | Yes | 2.057 | 10,203 | 20.99 k | 501,039 |
News
Craig-Hallum Initiates Coverage On Cerus with Buy Rating, Announces Price Target of $5
12 Apr 24
Perion Network Cuts Sales Outlook, Joins Range Resources And Other Big Stocks Moving Lower In Monday's Pre-Market Session
8 Apr 24
12 Health Care Stocks Moving In Friday's After-Market Session
5 Apr 24
Cerus Corporation Announces FDA Approval Of Extended Shelf Life For INTERCEPT Platelet Processing Sets, Doubling Previous Shelf Life
26 Mar 24
Cathie Wood's Ark Invest Sells Another Tranche Of Block Shares, Even As Bitcoin Price Stages A Recovery
20 Mar 24
Press releases
Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life
26 Mar 24
Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results
5 Mar 24
Cerus Corporation to Participate in Upcoming Investor Conferences
1 Feb 24